Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference

PR Newswire February 6, 2023

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA's Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

GlobeNewswire January 26, 2023

REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients

PR Newswire January 23, 2023

REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS

PR Newswire January 9, 2023

REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2023

REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease

PR Newswire December 21, 2022

REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I

PR Newswire December 8, 2022

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire November 22, 2022

REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

PR Newswire November 3, 2022

REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

PR Newswire November 3, 2022

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire November 2, 2022

REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy

PR Newswire October 27, 2022

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical's Proprietary Suprachoroidal Space Platform

GlobeNewswire October 4, 2022

REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD

PR Newswire October 3, 2022

REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

PR Newswire September 27, 2022

REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting

PR Newswire September 26, 2022

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire September 6, 2022

REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE(TM) Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium

PR Newswire August 31, 2022

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

PR Newswire August 23, 2022

REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

PR Newswire August 10, 2022